Abstracts tagged "ankylosing spondylitis (AS) and diagnosis"

Abstract Number: 2726 • 2016 ACR/ARHP Annual Meeting
Prevalence of HLA-B27 in the Normal Population and Patients with Axial Spondyloarthritis in Saudi Arabia
Fatima alduraibi¹, Mohammed Omair^2,3, Moheeb Al Awwami⁴, Sultana Abdulaziz⁵, Waleed Husain⁶, Maha El Dessougi⁷, Mahmoud Aljurf⁸, Hind Alhumaidan⁹, Hana Al Khabbaz¹⁰, Ibrahim Alahmadi¹¹ and Salman Al Saleh¹², ¹Department of Internal Medicine, Section of Rheumatology ,Department of Internal Medicine,King Faisal Specialsed Hospital, Saudi Arabia, Riyadh, Saudi Arabia, ²Rheumatology, King Khalid Hospital, Riyadh, ON, Saudi Arabia, ³Division of Rheumatology, Department of Medicine, King Saud University, Riyadh, Saudi Arabia, ⁴Histocompatibility and Immunogenetics Laboratory, Department of Pathology and Laboratory Medicine, King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia, ⁵Dept of Medicine/Unit of Rheumatology, King Fahad Hospital, Jeddah, Saudi Arabia, ⁶Hera Hospital , Division of Rheumatology, Department of Medicine, Makkah, Saudi Arabia, ⁷Security Forces Hospital Division of Rheumatology, Department of Medicine, Riyadh, Saudi Arabia, ⁸Department of Adult Hematology/Oncology and Stem Cell Transplantation, King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia, ⁹Blood Bank/Stem Cell/Cord Blood , Department of Pathology and Laboratory Medicine, King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia, ¹⁰Riyadh Colleges of Dentistry and Pharmacy, Riyadh, Saudi Arabia, ¹¹Organ Transplant Center, King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia, ¹²King Faisal Specialsed Hospital, Riyadh, Saudi Arabia
Background/Purpose: The prevalence of HLA-B27 varies between different ethnicities. Its presence is associated with susceptibility to axial spondyloarthritis (axSpA). The aim of this study is…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].